Lipid-mediated steatosis sensitises hepatocytes to the adverse effects of doxorubicin

ABSTRACT: The incidence of obesity and its related morbidities has rapidly increased over the past twenty years. One consequence of this is the increased probability of having to treat obese individuals for breast cancer. An important co-morbidity associated with obesity are the spectrum of fatty liver diseases. As such, an important question is how treatment of breast cancer with standard therapeutic agents may alter in individuals with fatty liver disease. Such impacts could result in an enhanced adverse effect profile over both acute (e.g. increased cytotoxicity against non-malignant tissues) or chronic (e.g. increased progression through the fatty liver disease spectrum) time periods. In this work we examine if lipid loading in human hepatocytes, leading to a steatotic phenotype, results in an a

ORGANISM(S): Homo sapiens

SUBMITTER: Vytautas Leoncikas 

PROVIDER: E-MTAB-3523 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress